VERONA PHARMA P/S (NASDAQ:VRNA) and Obseva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
This is a breakdown of current ratings and price targets for VERONA PHARMA P/S and Obseva, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|VERONA PHARMA P/S||0||0||3||0||3.00|
VERONA PHARMA P/S presently has a consensus target price of $33.67, indicating a potential upside of 582.55%. Obseva has a consensus target price of $32.00, indicating a potential upside of 209.48%. Given VERONA PHARMA P/S’s higher possible upside, analysts clearly believe VERONA PHARMA P/S is more favorable than Obseva.
Volatility & Risk
VERONA PHARMA P/S has a beta of -1, meaning that its stock price is 200% less volatile than the S&P 500. Comparatively, Obseva has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.
Valuation & Earnings
This table compares VERONA PHARMA P/S and Obseva’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|VERONA PHARMA P/S||N/A||N/A||-$26.56 million||($2.02)||-2.44|
Obseva is trading at a lower price-to-earnings ratio than VERONA PHARMA P/S, indicating that it is currently the more affordable of the two stocks.
This table compares VERONA PHARMA P/S and Obseva’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|VERONA PHARMA P/S||N/A||-15.56%||-13.26%|
Insider & Institutional Ownership
56.1% of VERONA PHARMA P/S shares are owned by institutional investors. Comparatively, 63.6% of Obseva shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
VERONA PHARMA P/S beats Obseva on 5 of the 9 factors compared between the two stocks.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.